If you have been reading about nasal drops and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
=== Computing === cp (Unix), a UNIX command for copying files and directories Certificate policy, outlining (non)-intended uses of a digital certificate Circuit Probe, a method of wafer testing Code page, a table identifying the character set used to encode a set of glyphs Constraint programming, a programming paradigm wherein relations between variables are stated in the form of constraints Control Program, part of an operating system of the late 1960s; see CP/CMS Connection pool, a cache of database connections 'Content Profile' in the NISO standard Content Profile/Linked Document, a data serialisation format Child process, computing process created by another process Adobe Captivate, a software application
The Rhodesian Bush War, a guerrilla conflict between the government and two rival communist-backed black Rhodesian groups, began in earnest two years later, and after several attempts to end the war Smith concluded the Internal Settlement with non-militant nationalists in 1978. Under these terms the country was reconstituted under black rule as Zimbabwe Rhodesia in June 1979, but this new order was rejected by the guerrillas and the international community. The Bush War continued until Zimbabwe Rhodesia revoked its UDI as part of the Lancaster House Agreement in December 1979. Following a brief period of direct British rule, the country was granted internationally recognised independence under the name Zimbabwe in 1980.
Experiments confirm that UV-B light is necessary for parietin synthesis—under controlled conditions, thalli exposed only to photosynthetically active radiation (PAR) regenerated 12% of their parietin, while those exposed to UV-B restored 35%. Despite lower UV-B levels in Arctic environments, X. parietina maintains high parietin concentrations, suggesting that additional environmental factors regulate its production. Seasonal field studies show that parietin levels in Xanthoria parietina follow an annual cycle. In naturally occurring populations, concentrations were lowest in winter and nearly doubled by the summer solstice. This pattern mirrors seasonal shifts in UV-B radiation, suggesting that parietin synthesis is rapidly upregulated in spring to shield the photobiont from excess light and declines more gradually in autumn as irradiance decreases. In addition to parietin, X. parietina produces several related anthraquinones, including fallacinol (also called teloschistin), fallacinal, emodin, and parietinic acid. Fallacinol and fallacinal are minor anthraquinones, while emodin is another orange pigment found in some lichens. These compounds contribute to the chemical profile of X. parietina and have been investigated in phytochemical studies. Recent research (2023) has explored X. parietina as a natural source of anthraquinones for synthesizing pharmaceutical derivatives, such as O-methylated and acylated anthraquinones. X. parietina also produces the secondary metabolite 2-methoxy-4,5,7-trihydroxy-anthraquinone, as well as tocopherol and ergosterol.
Eptifibatide and tirofiban are anti-clotting drugs indicated to prevent thrombosis in acute ischemic coronary syndromes. Eptifibatide is additionally FDA approved for patients undergoing percutaneous coronary intervention. These drugs block activation of the integrin responsible for aggregation of platelets (αIIbβ3, also known as glycoprotein IIb/IIIa) in response to the blood glycoproteins fibrinogen and von Willebrand factor. Eptifibatide (marketed as Integrilin) is a cyclic (circular) seven amino acid peptide, whereas tirofiban is a small molecule designed to mimic the chemistry and binding affinity of the RGD sequence.
Sources: en.wikipedia.org
== Functional features == Observations of limiting enzymatic hydrolysis elicited by trypsin in a controlled environment have shown an increase in hemp protein isolate (HSI) solubility at various pH and a notable decrease in the recorded emulsifying activity index.
=== Novel mAb development technology === Several monoclonal antibody technologies were developed in the period from the 1970s to the late 2010s, such as phage display, single B cell culture, single cell amplification from various B cell populations and single plasma cell interrogation technologies. Different from traditional hybridoma technology, the more recent technologies use molecular biology techniques to amplify the heavy and light chains of the antibody genes by PCR and produce in either bacterial or mammalian systems with recombinant technology. One of the advantages of the new technologies is their applicability to multiple animals, such as rabbit, llama, chicken and other common experimental animals in the laboratory.
=== Pathogen reduction of red cells === Pathogen reduction is a technology predominantly used to reduce the risk of transfusion-transmitted infectious diseases and bacterial contamination. The principle resembles the one of irradiation: by adding an agent which interferes with the replication process of DNA or RNA, any present pathogen, as well as any residual leucocytes, will not be able to replicate further. Systems for pathogen inactivation of red blood cells are still awaiting market authorisation. However, studies suggest that the red blood cell quality is not negatively impacted by this processing procedure, which indicates that pathogen inactivation may be a suitable future substitute for irradiation and potentially also washing of red blood cells.
=== Pregnancy and lactation === Studies on whether or not the use of clindamycin/benzoyl peroxide gels is teratogenic or has adverse effects on nursing infants have not been performed. While oral clindamycin passes into breast milk, no such data are available for clindamycin in gel form. Limited data regarding topical clindamycin and benzoyl peroxide have shown no safety problems.
Senator, I am not now, nor have I ever been, an oil trader—and neither has anyone on my behalf. I have never seen a barrel of oil, owned one, bought one, sold one—and neither has anyone on my behalf. Now I know that standards have slipped in the last few years in Washington, but for a lawyer you are remarkably cavalier with any idea of justice. I am here today but last week you already found me guilty. You traduced my name around the world without ever having asked me a single question, without ever having contacted me, without ever having written to me or telephoned me, without any attempt to contact me whatsoever, and you call that justice. Galloway countered the charges by claiming they were politically motivated and a "smokescreen". He accused Coleman and other pro-war politicians of covering up the "theft of billions of dollars of Iraq's wealth". He claimed this happened "on your watch" under the post-invasion Coalition Provisional Authority, and was committed by "Halliburton and other American corporations ... with the connivance of your own government".
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.